Curated News
By: NewsRamp Editorial Staff
May 16, 2025
Silo Pharma Announces Pricing of Public Offering and Development of Novel Therapeutics
TLDR
- Investors can benefit from Silo Pharma's public offering of 3.33 million shares at $0.60 per unit, expected to raise $2 million.
- Silo Pharma priced a public offering with 3.33 million shares at $0.60 each, including Series A-1 and A-2 warrants with specific expiration dates.
- Silo Pharma's funding from the public offering will support research into therapies for stress-induced disorders and CNS diseases, aiming to improve mental health treatments.
- Silo Pharma's lead program, SPC-15, offers an intranasal treatment for PTSD, showing promise in addressing underserved conditions like chronic pain and stress-induced disorders.
Impact - Why it Matters
This news matters as it highlights Silo Pharma's latest public offering and its focus on developing innovative treatments for various disorders. Investors and individuals interested in biopharmaceutical advancements should take note of Silo Pharma's progress in addressing unmet medical needs. The company's commitment to developing novel therapies could potentially impact the treatment landscape for stress-induced psychiatric disorders, chronic pain conditions, and CNS diseases.
Summary
Silo Pharma (NASDAQ: SILO) has priced a public offering of approximately 3.33 million shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants, all priced at $0.60 per unit. Gross proceeds are expected to total roughly $2 million before fees and expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent, and proceeds will support general working capital.
Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (“CNS”) diseases. The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. Silo’s research and development programs are conducted through collaborations with universities and independent laboratories.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Announces Pricing of Public Offering and Development of Novel Therapeutics
